Endonovo Appoints Samir Awad, M.D., to Scientific Advisory Board
September 09, 2019 at 06:30 pm IST
Share
Endonovo Therapeutics, Inc. announced the appointment of Dr. Sam Awad to its scientific advisory board. Dr. Samir S. Awad has worked for Baylor College of Medicine and the Michael E. DeBakey VAMC since 2000. He has served as the Operative Care Line executive, chief of general surgery, and medical director of the Surgical Intensive Care Unit at the MEDVAMC. Dr. Awad's areas of specialty include surgical oncology, abdominal wall reconstruction and acute care surgery, as well as minimally invasive laparoscopic and robotic surgical procedures. He is a member of the Association for Academic Surgeons, the Society of University Surgeons, the American College of Surgeons, the Surgical Infection Society, and the Society for Critical Care Medicine.
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
ENDONOVO THERAPEUTICS, INC. 
